NEW YORK, Dec. 21 (GenomeWeb News) - Oslo-based Affitech announced recently that it has licensed its phage display technology to Dyax, of Cambridge, Mass.
Dyax is the first licensee of Affitech's core patent portfolio, which covers phagemid display of antibodies and antibody fragments, Affitech said. Specifically, the worldwide patent covers the use of full-length pIII phage protein as a scaffold in a phagemid vector.
Affitech obtained the exclusive worldwide rights to the patent from the DKFZ (German Cancer Research Center) in Heidelberg, Germany.
Financial terms of the deal were not disclosed.